Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

08 janv. 2026 08h45 HE | Source: Biofrontera Inc.

Biofrontera Inc. Announces Data Base Locks for Two Clinical Studies Supporting Key Data and Regulatory Milestones

Database locks for studies on actinic keratosis (AK) and acne vulgaris achieved on January 5, 2026Data generated will support key regulatory milestones for Ameluz PDT in both indicationsAK and acne...
05 janv. 2026 09h15 HE | Source: Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study

Interim safety and efficacy data to be reported in Q1 VERO BEACH, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company...
22 déc. 2025 07h00 HE | Source: Propanc Biopharma, Inc.

Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal

Our findings demonstrate that PRP exerts multifaceted effects specifically over the cancer associated fibroblasts (CAFs) population and tumor cells.
16 déc. 2025 16h15 HE | Source: MAIA Biotechnology, Inc.

MAIA Biotechnology Announces $1.51 Million Private Placement

CHICAGO, IL, Dec. 16, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies...
08 déc. 2025 06h00 HE | Source: Greenwich LifeSciences, Inc.

Greenwich LifeSciences Announces Completion of Enrollment in the Open Label Arm of FLAMINGO-01

STAFFORD, Texas, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
04 déc. 2025 08h45 HE | Source: Propanc Biopharma, Inc.

Propanc Biopharma Investigates “Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs

"Our cells naturally become more mesenchymal over time, so PRP’s ability to potentially reverse this trend is of tremendous scientific interest"
03 déc. 2025 07h45 HE | Source: Greater Cannabis Company, Inc.

GCANRx Announces Relisting To OTCQB Market Tier

Baltimore, Dec. 03, 2025 (GLOBE NEWSWIRE) -- The Greater Cannabis Company, Inc. (OTC: GCAN) (“the Company”), a clinical stage biopharmaceutical company focused on the development of new and...
03 déc. 2025 06h00 HE | Source: Greenwich LifeSciences, Inc.

Greenwich LifeSciences Provides Global Update on FLAMINGO-01, Screening Over 1,000 Patients to Date

STAFFORD, Texas, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
02 déc. 2025 08h45 HE | Source: Biofrontera Inc.

Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of Superficial Basal Cell Carcinoma (sBCC) with Ameluz®-PDT

sNDA for treatment of sBCC with Ameluz®-PDT submitted to U.S. Food and Drug Administration (FDA) on November 28, 2025First Phase 3 PDT study in patients with sBCC in the United States submitted to...
17 nov. 2025 08h45 HE | Source: Propanc Biopharma, Inc.

Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results

“Our first quarter delivered meaningful progress across clinical, financial, and strategic initiatives,” said James Nathanielsz, CEO of Propanc.

Page suivante